Comparison of National and Global Asthma Management Guiding Documents

REFERENCES

1. 1.↵
   Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1204-22.
2. 2.↵
   1. Enilari O,
   2. Sinha S

   . The Global Impact of Asthma in Adult Populations. Ann Glob Health 2019;85(1):2.

   OpenUrl
3. 3.↵
   1. Yaghoubi M,
   2. Adibi A,
   3. Safari A,
   4. FitzGerald JM,
   5. Sadatsafavi M

   . The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med 2019;200(9):1102-1112.

   OpenUrlCrossRefPubMed
4. 4.↵
   National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program (NAEPP). https://www.nhlbi.nih.gov/science/national-asthma-education-and-prevention-program-naepp. Accessed February 21, 2022.
5. 5.↵
   Global Initiative for Asthma. About us. https://ginasthma.org/about-us/. Accessed February 21, 2022.
6. 6.↵
   National Asthma Education Program (NAEP). The Expert Panel Report on the Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: 1991.
7. 7.↵
   National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda MD: US Department of Health and Human Services, National Institute of Health, 1997: publication no. 97-4051.
8. 8.↵
   National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Quick reference for the NAEPP Expert Panel Report: Guidelines for the diagnosis and management of asthma--Update on selected topics 2002. Bethesda MD: US Department of Health and Human Services, National Institute Health, 2002;publication no. 02-5075.
9. 9.↵
   National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel on the Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2007.
10. 10.↵
    Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020;146(6):1217-1270.
11. 11.↵
    Global Initiative for Asthma. Archived reports. https://ginasthma.org/archived-reports/. Accessed February 21, 2022.
12. 12.↵
    Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention Available at: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf. Accessed May 1, 2022.
13. 13.↵
    Centers for Disease Control and Prevention. Most recent national asthma data. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed May 1, 2022.
14. 14.
    1. Bacharier LB

    . Viral-induced wheezing episodes in preschool children: approaches to therapy. Curr Opin Pulm Med 2010;16(1):31-35.

    OpenUrlPubMed
15. 15.↵
    1. Garcia-Marcos L,
    2. Mallol J,
    3. Sole D,
    4. Brand PLP

    , EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. Pediatr Allergy Immunol 2010;21(5):878-888.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Martinez FD,
    2. Wright AL,
    3. Taussig LM,
    4. Holberg CJ,
    5. Halonen M,
    6. Morgan WJ

    . Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332(3):133-8.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Mallol J,
    2. García-Marcos L,
    3. Solé D,
    4. Brand P

    , EISL Study Group. International prevalence of recurrent wheezing during the first year of life: variability, treatment patterns and use of health resources. Thorax 2010;65(11):1004-1009.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Ducharme FM,
    2. Lemire C,
    3. Noya FJD,
    4. Davis GM,
    5. Alos N,
    6. Leblond H,
    7. et al

    . Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009;360(4):339-353.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Kaiser SV,
    2. Huynh T,
    3. Bacharier LB,
    4. Rosenthal JL,
    5. Bakel LA,
    6. Parkin PC,
    7. Cabana MD

    . Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics 2016;137(6):e210154496.

    OpenUrl
20. 20.↵
    1. Bacharier LB,
    2. Phillips BR,
    3. Zeiger RS,
    4. Szefler SJ,
    5. Martinez FD,
    6. Lemanske RF Jr.,
    7. et al

    ; CARE Network. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008;122(6):1127-1135.e8.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Svedmyr J,
    2. Nyberg E,
    3. Thunqvist P,
    4. Asbrink-Nilsson E,
    5. Hedlin G

    . Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr 1999;88(1):42-47.

    OpenUrlPubMedWeb of Science
22. 22.↵
    1. Smith C,
    2. Goldman RD

    . Nebulizers versus pressurized metered-dose inhalers in preschool children with wheezing. Can Fam Physician 2012;58(5):528-530.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Stanković I,
    2. Pejcić T,
    3. Milenković B,
    4. Jovanović D,
    5. Rancić M

    . Is there any point in a corticosteroid treatment of intermittent asthma? ScientificWorldJournal 2007;7:1082-1089.

    OpenUrlPubMed
24. 24.↵
    1. Bender B,
    2. Milgrom H,
    3. Rand C

    . Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol 1997;79(3):177-185, quiz 185-186.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Engelkes M,
    2. Janssens HM,
    3. de Jongste JC,
    4. Sturkenboom MCJM,
    5. Verhamme KMC

    . Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J 2015;45(2):396-407.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Brown MT,
    2. Bussell JK

    . Medication adherence: WHO cares? Mayo Clin Proc 2011;86(4):304-314.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011;377(9766):650-7.
28. 28.↵
    1. Camargos P,
    2. Affonso A,
    3. Calazans G,
    4. Ramalho L,
    5. Ribeiro ML,
    6. Jentzsch N,
    7. et al

    . On-demand intermittent beclomethasone is effective for mild asthma in Brazil. Clin Transl Allergy 2018;8:7.

    OpenUrl
29. 29.
    1. Turpeinen M,
    2. Nikander K,
    3. Pelkonen AS,
    4. Syvanen P,
    5. Sorva R,
    6. Raitio H,
    7. et al

    . Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 2008;93(8):654-659.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Boushey HA,
    2. Sorkness CA,
    3. King TS,
    4. Sullivan SD,
    5. Fahy JV,
    6. Lazarus SC,
    7. et al

    ; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352(15):1519-1528.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Selroos O

    . A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid. Ther Clin Risk Manag 2007;3(2):349-359.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Cusack RP,
    2. Satia I,
    3. O'Byrne PM

    . Asthma maintenance and reliever therapy: should this be the standard of care? Ann Allergy Asthma Immunol 2020;125(2):150-155.

    OpenUrlPubMed
33. 33.↵
    1. Welsh EJ,
    2. Cates CJ

    . Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev 2010(9):CD008418.
34. 34.↵
    1. Bell AD,
    2. McIvor RA

    . The SMART study. Can Fam Physician 2007;53(4):687-688.

    OpenUrlFREE Full Text
35. 35.↵
    1. van Noord JA,
    2. Smeets JJ,
    3. Raaijmakers JA,
    4. Bommer AM,
    5. Maesen FP

    . Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9(8):1684-1688.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. O'Byrne PM,
    2. FitzGerald JM,
    3. Bateman ED,
    4. Barnes PJ,
    5. Zhong N,
    6. Keen C,
    7. et al

    . Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018;378(20):1865-1876.

    OpenUrlCrossRefPubMed
37. 37.
    1. Beasley R,
    2. Holliday M,
    3. Reddel HK,
    4. Braithwaite I,
    5. Ebmeier S,
    6. Hancox RJ,
    7. et al

    ; Novel START Study Team. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019;380(21):2020-2030.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Sobieraj DM,
    2. Weeda ER,
    3. Nguyen E,
    4. Coleman CI,
    5. White CM,
    6. Lazarus SC,
    7. et al

    . Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018;319(14):1485-1496.

    OpenUrlPubMed
39. 39.
    1. Bateman ED,
    2. Reddel HK,
    3. O'Byrne PM,
    4. Barnes PJ,
    5. Zhong N,
    6. Keen C,
    7. et al

    . As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018;378(20):1877-1887.

    OpenUrlCrossRefPubMed
40. 40.
    1. Pauwels RA,
    2. Löfdahl CG,
    3. Postma DS,
    4. Tattersfield AE,
    5. O'Byrne P,
    6. Barnes PJ,
    7. Ullman A

    . Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20):1405-1411.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Hardy J,
    2. Baggott C,
    3. Fingleton J,
    4. Reddel HK,
    5. Hancox RJ,
    6. Harwood M,
    7. et al

    . PRACTICAL study team. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019;394(10202):919-928.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Weiler JM,
    2. Bonini S,
    3. Coifman R,
    4. Craig T,
    5. Delgado L,
    6. Capao-Filipe M,
    7. et al

    ; Ad Hoc Committee of Sports Medicine Committee of American Academy of Allergy, Asthma & Immunology. American Academy of Allergy, Asthma & Immunology Work Group report: exercise-induced asthma. J Allergy Clin Immunol 2007;119(6):1349-1358.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. Lazarinis N,
    2. Jorgensen L,
    3. Ekstrom T,
    4. Bjermer L,
    5. Dahlen B,
    6. Pullerits T,
    7. et al

    . Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014;69(2):130-136.

    OpenUrlAbstract/FREE Full Text
44. 44.↵
    1. Harrison TW,
    2. Oborne J,
    3. Newton S,
    4. Tattersfield AE

    . Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363(9405):271-275.

    OpenUrlCrossRefPubMedWeb of Science
45. 45.
    1. FitzGerald JM,
    2. Becker A,
    3. Sears MR,
    4. Mink S,
    5. Chung K,
    6. Lee J

    , Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004;59(7):550-556.

    OpenUrlAbstract/FREE Full Text
46. 46.↵
    1. Oborne J,
    2. Mortimer K,
    3. Hubbard RB,
    4. Tattersfield AE,
    5. Harrison TW

    . Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009;180(7):598-602.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.↵
    1. Jackson DJ,
    2. Bacharier LB,
    3. Mauger DT,
    4. Boehmer S,
    5. Beigelman A,
    6. Chmiel JF,
    7. et al

    ; National Heart, Lung, and Blood Institute AsthmaNet. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. N Engl J Med 2018;378(10):891-901.

    OpenUrlCrossRefPubMed
48. 48.↵
    1. McKeever T,
    2. Mortimer K,
    3. Wilson A,
    4. Walker S,
    5. Brightling C,
    6. Skeggs A,
    7. et al

    . Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med 2018;378(10):902-910.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. Lahdensuo A,
    2. Haahtela T,
    3. Herrala J,
    4. Kava T,
    5. Kiviranta K,
    6. Kuusisto P,
    7. et al

    . Randomised comparison of guided self management and traditional treatment of asthma over one year. BMJ 1996;312(7033):748-752.

    OpenUrlAbstract/FREE Full Text
50. 50.↵
    1. Buels KS,
    2. Fryer AD

    . Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol 2012(208):317-341.
51. 51.↵
    1. Lee LA,
    2. Yang S,
    3. Kerwin E,
    4. Trivedi R,
    5. Edwards LD,
    6. Pascoe S

    . The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med 2015;109(1):54-62.

    OpenUrlCrossRefPubMed
52. 52.
    1. Peters SP,
    2. Kunselman SJ,
    3. Icitovic N,
    4. Moore WC,
    5. Pascual R,
    6. Ameredes BT,
    7. et al

    ; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363(18):1715-1726.

    OpenUrlCrossRefPubMedWeb of Science
53. 53.
    1. Bateman ED,
    2. Kornmann O,
    3. Schmidt P,
    4. Pivovarova A,
    5. Engel M,
    6. Fabbri LM

    . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011;128(2):315-322.

    OpenUrlCrossRefPubMedWeb of Science
54. 54.
    1. Kerstjens HA,
    2. Moroni-Zentgraf P

    . Tiotropium add-on therapy in patients with uncontrolled asthma. Int J Tuberc Lung Dis 2015;19(12):1553.

    OpenUrl
55. 55.↵
    1. Rodrigo GJ,
    2. Neffen H

    . Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: a systematic review. Pediatr Allergy Immunol 2017;28(6):573-578.

    OpenUrl
56. 56.↵
    1. Rajanandh MG,
    2. Nageswari AD,
    3. Ilango K

    . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clin Ther 2014;36(4):526-533.

    OpenUrl
57. 57.
    1. Rajanandh MG,
    2. Nageswari AD,
    3. Ilango K

    . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clin Ther 2015;37(2):418-426.

    OpenUrl
58. 58.
    1. Virchow JC,
    2. Kuna P,
    3. Paggiaro P,
    4. Papi A,
    5. Singh D,
    6. Corre S,
    7. et al

    . Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019;394(10210):1737-1749.

    OpenUrlPubMed
59. 59.↵
    1. Lee LA,
    2. Bailes Z,
    3. Barnes N,
    4. Boulet L-P,
    5. Edwards D,
    6. Fowler A,
    7. et al

    . Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021;9(1):69-84.

    OpenUrl
60. 60.↵
    1. Kew KM,
    2. Dahri K

    . Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016(1):CD011721.
61. 61.↵
    1. Casale TB,
    2. Aalbers R,
    3. Bleecker ER,
    4. Meltzer EO,
    5. Zaremba-Pechmann L,
    6. de la Hoz A,
    7. Kerstjens HAM

    . Tiotropium Respimat^(R) add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics. Respir Med 2019;158:97-109.

    OpenUrl
62. 62.↵
    1. Riise GC,
    2. Torén K,
    3. Olin AC

    . Subjects in a population study with high levels of FENO have associated eosinophil airway inflammation. ISRN Allergy 2011;2011:792613.

    OpenUrl
63. 63.↵
    1. Price DB,
    2. Buhl R,
    3. Chan A,
    4. Freeman D,
    5. Gardener E,
    6. Godley C,
    7. et al

    . Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med 2018;6(1):29-39.

    OpenUrl
64. 64.
    1. Heaney LG,
    2. Busby J,
    3. Bradding P,
    4. Chaudhuri R,
    5. Mansur AH,
    6. Niven R,
    7. et al

    ; Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK). Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med 2019;199(4):454-464.

    OpenUrlPubMed
65. 65.↵
    1. Price D,
    2. Ryan D,
    3. Burden A,
    4. Von Ziegenweidt J,
    5. Gould S,
    6. Freeman D,
    7. et al

    . Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. Clin Transl Allergy 2013;3(1):37.

    OpenUrlCrossRefPubMed
66. 66.↵
    American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171(8):912-930.

    OpenUrlCrossRefPubMedWeb of Science
67. 67.↵
    Irvin CG Pulmonary Function Testing in Asthma. In: UpToDate. https://www.uptodate.com/contents/pulmonary-function-testing-in-asthma#H7. Accessed 20.
68. 68.↵
    1. Dweik RA,
    2. Boggs PB,
    3. Erzurum SC,
    4. Irvin CG,
    5. Leigh MW,
    6. Lundberg JO,
    7. et al

    ; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184(5):602-615.

    OpenUrlCrossRefPubMedWeb of Science
69. 69.↵
    1. Garg Y,
    2. Kakria N,
    3. Katoch CDS,
    4. Bhattacharyya D

    . Exhaled nitric oxide as a guiding tool for bronchial asthma: a randomised controlled trial. Med J Armed Forces India 2020;76(1):17-22.

    OpenUrl
70. 70.↵
    1. Honkoop PJ,
    2. Loijmans RJB,
    3. Termeer EH,
    4. Snoeck-Stroband JB,
    5. van den Hout WB,
    6. Bakker MJ,
    7. et al

    ; Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol 2015;135(3):682-688.e11.

    OpenUrlCrossRef
71. 71.↵
    1. Petsky HL,
    2. Kew KM,
    3. Chang AB

    . Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev 2016;11:CD011439.

    OpenUrlCrossRefPubMed
72. 72.↵
    1. Beck-Ripp J,
    2. Griese M,
    3. Arenz S,
    4. Köring C,
    5. Pasqualoni B,
    6. Bufler P

    . Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J 2002;19(6):1015-1019.

    OpenUrlAbstract/FREE Full Text
73. 73.↵
    1. Szefler SJ,
    2. Mitchell H,
    3. Sorkness CA,
    4. Gergen PJ,
    5. O'Connor GT,
    6. Morgan WJ,
    7. et al

    . Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372(9643):1065-1072.

    OpenUrlCrossRefPubMedWeb of Science
74. 74.
    1. Vijverberg SJH,
    2. Koster ES,
    3. Koenderman L,
    4. Arets HGM,
    5. van der Ent CK,
    6. Postma DS,
    7. et al

    . Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study. Pediatr Allergy Immunol 2012;23(6):529-536.

    OpenUrlCrossRefPubMed
75. 75.↵
    1. Baraldi E

    1. de Jongste JC,
    2. Carraro S,
    3. Hop WC

    , CHARISM Study Group; Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009;179(2):93-97.

    OpenUrlCrossRefPubMedWeb of Science
76. 76.↵
    1. Fritsch M,
    2. Uxa S,
    3. Horak F Jr.,
    4. Putschoegl B,
    5. Dehlink E,
    6. Szepfalusi Z,
    7. Frischer T

    . Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. Pediatr Pulmonol 2006;41(9):855-862.

    OpenUrlCrossRefPubMedWeb of Science
77. 77.↵
    American Academy of Allergy Asthma and Immunology. Indoor allergens. Updated September 28, 2020. https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/indoor-allergens-. Accessed March 3, 2022.
78. 78.↵
    United States Environmental Protection Agency. Asthma triggers: gain control. https://www.epa.gov/asthma/asthma-triggers-gain-control. Accessed March 21, 2022.
79. 79.↵
    1. Leas BF,
    2. D'Anci KE,
    3. Apter AJ,
    4. Bryant-Stephens T,
    5. Lynch MP,
    6. Kaczmarek JL,
    7. Umscheid CA

    . Effectiveness of indoor allergen reduction in asthma management: a systematic review. J Allergy Clin Immunol 2018;141(5):1854-1869.

    OpenUrl
80. 80.↵
    1. Levy JI,
    2. Brugge D,
    3. Peters JL,
    4. Clougherty JE,
    5. Saddler SS

    . A community-based participatory research study of multifaceted in-home environmental interventions for pediatric asthmatics in public housing. Soc Sci Med 2006;63(8):2191-2203.

    OpenUrlCrossRefPubMed
81. 81.↵
    1. Crocker DD,
    2. Kinyota S,
    3. Dumitru GG,
    4. Ligon CB,
    5. Herman EJ,
    6. Ferdinands JM,
    7. et al

    ; Task Force on Community Preventive Services. Effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthma morbidity: a community guide systematic review. Am J Prev Med 2011;41(2 Suppl 1):S5-S32.

    OpenUrlCrossRefPubMed
82. 82.↵
    1. Nathan RA

    . The burden of allergic rhinitis. Allergy Asthma Proc 2007;28(1):3-9.

    OpenUrlCrossRefPubMedWeb of Science
83. 83.↵
    1. de Groot EP,
    2. Nijkamp A,
    3. Duiverman EJ,
    4. Brand PLP

    . Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax 2012;67(7):582-587.

    OpenUrlAbstract/FREE Full Text
84. 84.↵
    American Academy of Allergy Asthma and Immunology. Is your asthma allergic? Updated Sept 28, 2020. https://www.aaaai.org/Tools-for-the-Public/Conditions-Library/Asthma/Is-Your-Asthma-Allergic. Accessed March 13, 2022.
85. 85.↵
    American College of Allergy, Asthma, and Immunology. Allergy immunology. https://acaai.org/allergies/management-treatment/allergy-immunotherapy/. Accessed March 14, 2022.
86. 86.↵
    1. Schulten V,
    2. Tripple V,
    3. Aasbjerg K,
    4. Backer V,
    5. Lund G,
    6. Wurtzen PA,
    7. et al

    . Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy. Clin Exp Allergy 2016;46(3):439-448.

    OpenUrl
87. 87.↵
    1. Abramson MJ,
    2. Puy RM,
    3. Weiner JM

    . Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010(8):CD001186.
88. 88.↵
    1. Gomez Vera J,
    2. Flores Sandoval G,
    3. Orea Solano M,
    4. López Tiro J,
    5. Jiménez Saab N

    . Safety and efficacy of specific sublingual immunotherapy in patients with asthma and allergy to Dermatophagoides pteronyssinus. Rev Alerg Mex 2005;52(6):231-236.

    OpenUrl
89. 89.
    1. Virchow JC,
    2. Backer V,
    3. Kuna P,
    4. Prieto L,
    5. Nolte H,
    6. Villesen HH,
    7. et al

    . Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA 2016;315(16):1715-1725.

    OpenUrlCrossRefPubMed
90. 90.
    1. de Blay F,
    2. Kuna P,
    3. Prieto L,
    4. Ginko T,
    5. Seitzberg D,
    6. Riis B,
    7. Canonica GW

    . SQ HDM SLIT-tablet (ALK) in treatment of asthma-post hoc results from a randomised trial. Respir Med 2014;108(10):1430-1437.

    OpenUrl
91. 91.
    1. Devillier P,
    2. Fadel R,
    3. de Beaumont O

    . House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. Allergy 2016;71(2):249-257.

    OpenUrl
92. 92.
    1. Marogna M,
    2. Braidi C,
    3. Bruno ME,
    4. Colombo C,
    5. Colombo F,
    6. Massolo A,
    7. et al

    . The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr) 2013;41(4):216-224.

    OpenUrl
93. 93.
    1. Mosbech H,
    2. Canonica GW,
    3. Backer V,
    4. de Blay F,
    5. Klimek L,
    6. Broge L,
    7. Ljorring C L

    . SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol 2015;114(2):134-140.

    OpenUrl
94. 94.
    1. Wang L,
    2. Yin J,
    3. Fadel R,
    4. Montagut A,
    5. de Beaumont O,
    6. Devillier P

    . House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 2014;69(9):1181-1188.

    OpenUrl
95. 95.↵
    1. Rice JL,
    2. Diette GB,
    3. Suarez-Cuervo C,
    4. Brigham EP,
    5. Lin SY,
    6. Ramanathan M Jr.,
    7. et al

    . Allergen-specific immunotherapy in the treatment of pediatric asthma: a systematic review. Pediatrics 2018;141(5):e20173833.

    OpenUrlCrossRefPubMed
96. 96.↵
    1. Lin SY,
    2. Azar A,
    3. Suarez-Cuervo C,
    4. Diette GB,
    5. Brigham E,
    6. Rice J,
    7. et al

    . Role of sublingual immunotherapy in the treatment of asthma: an updated systematic review. Int Forum Allergy Rhinol 2018;8(9):982-992.

    OpenUrl
97. 97.↵
    1. Mosbech H,
    2. Deckelmann R,
    3. de Blay F,
    4. Pastorello EA,
    5. Trebas-Pietras E,
    6. Andres LP,
    7. et al

    . Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134(3):568-575.e7.

    OpenUrlCrossRef
98. 98.
    1. Marogna M,
    2. Colombo F,
    3. Spadolini I,
    4. Massolo A,
    5. Berra D,
    6. Zanon P,
    7. et al

    . Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. J Investig Allergol Clin Immunol 2010;20(2):146-152.

    OpenUrlPubMed
99. 99.
    1. Marogna M,
    2. Spadolini I,
    3. Massolo A,
    4. Berra D,
    5. Zanon P,
    6. Chiodini E,
    7. et al

    . Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009;102(1):69-75.

    OpenUrlPubMed
100. 100.↵
     1. Niu C-K,
     2. Chen W-Y,
     3. Huang J-L,
     4. Lue K-H,
     5. Wang J-Y

     . Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006;100(8):1374-1383.

     OpenUrlCrossRefPubMed
101. 101.↵
     Information from the American College of Allergy, Asthma, and Immunology. Sublingual (under the tongue) immunotherapy is an alternative way to treat allergies without injections. https://acaai.org/allergies/management-treatment/allergy-immunotherapy/slit/. Accessed April 2, 2022.
102. 102.↵
     1. d'Hooghe JNS,
     2. Ten Hacken NHT,
     3. Weersink EJM,
     4. Sterk PJ,
     5. Annema JT,
     6. Bonta PI

     . Emerging understanding of the mechanism of action of bronchial thermoplasty in asthma. Pharmacol Ther 2018;181:101-107.

     OpenUrl
103. 103.↵
     1. Castro M,
     2. Rubin AS,
     3. Laviolette M,
     4. Fiterman J,
     5. De Andrade Lima M,
     6. Shah PL,
     7. et al

     ; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181(2):116-124.

     OpenUrlCrossRefPubMedWeb of Science
104. 104.↵
     National Center for Complementary and Integrative Health. Placebo effect. Updated January 2020. Available at: https://www.nccih.nih.gov/health/placebo-effect. Accessed April 2, 2022.
105. 105.↵
     1. Wechsler ME,
     2. Laviolette M,
     3. Rubin AS,
     4. Fiterman J,
     5. Lapa e Silva JR,
     6. Shah PL,
     7. et al

     ; Asthma Intervention Research 2 Trial Study Group. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132(6):1295-1302.

     OpenUrlCrossRefPubMedWeb of Science
106. 106.↵
     World Health Organization. Coronavirus disease (COVID-19). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed April 19, 2022.
107. 107.↵
     1. Zhou F,
     2. Yu T,
     3. Du R,
     4. Fan G,
     5. Liu Y,
     6. Liu Z,
     7. et al

     . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-1062.

     OpenUrlCrossRefPubMed
108. 108.↵
     1. Pennington E,
     2. Yaqoob ZJ,
     3. Al-Kindi SG,
     4. Zein J

     . Trends in asthma mortality in the United States: 1999 to 2015. Am J Respir Crit Care Med 2019;199(12):1575-1577.

     OpenUrlPubMed
109. 109.↵
     1. Sunjaya AP,
     2. Allida SM,
     3. Di Tanna GL,
     4. Jenkins C

     . Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis. J Asthma 2022;59(5):866-879.

     OpenUrl
110. 110.↵
     1. Williamson EJ,
     2. Walker AJ,
     3. Bhaskaran K,
     4. Bacon S,
     5. Bates C,
     6. Morton CE,
     7. et al

     . Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430-436.

     OpenUrlCrossRefPubMed
111. 111.↵
     1. Liu S,
     2. Cao Y,
     3. Du T,
     4. Zhi Y

     . Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2021;9(2):693-701.

     OpenUrl